- Jane Mashingia, Technical Advisor, East African Community Medicines Regulatory Harmonization Program
- David Mukanga, Senior Program Officer of Regulatory Affairs, The Bill and Melinda Gates Foundation
- Margareth Ndomondo-Sigonda, Head of Health Unit, African Union Development Agency – New Partnership for Africa’s Development (AUDA-NEPAD)
- Jean Baptiste Nikiema, Regional Advisor for Essential Medicines, World Health Organization Africa Regional Office
- Jude Nwokike, Vice President, US Pharmacopeia; Director, USAID Promoting the Quality of Medicine Plus Program
- Andreas Seiter, Global Lead for the Private Sector, Health, Nutrition, and Population Global Practice, World Bank
- Javier Guzman, Director, Global Health Policy Program and Senior Policy Fellow, Center for Global Development
ABOUT THE EVENT
As of November 5, 2021, the African Union signed into force its second specialized health agency: the African Medicines Agency (AMA). More than two years after its introduction, the AMA treaty has now been ratified by 17 African Union member countries – two more than was required – and has been signed by many more, making it the latest regional partnership to strengthen capacity for medicines regulation and facilitate regulatory harmonization across the African continent in order to improve access to safe, effective, and quality-assured medicines. With high-level support secured, attention now must shift to strategic questions of how to operationalize AMA and set it up for success.
The African Medicines Regulatory Harmonization Partnership Platform meeting on February 3 covered plans for AMA to facilitate strong collaboration among members and support for the agency from the start. Following on this key meeting, join the Center for Global Development for a conversation around how to best structure AMA for greatest impact. Speakers will discuss the relationship between AMA and other national and regional regulatory institutions and efforts; potential funding arrangements to guarantee adequate capacity and sustainability; priority regulatory functions AMA should concentrate on in its first years of existence; and lessons learned from other regional efforts to strengthen regulatory harmonization.